BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 21763589)

  • 1. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
    Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
    Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.
    Tierney EP; Badger J
    MedGenMed; 2004 Sep; 6(3):4. PubMed ID: 15520626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.
    Corrias G; Horvat N; Monti S; Basturk O; Lin O; Saba L; Bodei L; Reidy DL; Mannelli L
    Medicine (Baltimore); 2017 Dec; 96(50):e9252. PubMed ID: 29390362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of necrolytic migratory erythema managed for 24 months with intravenous amino acid and lipid infusions.
    Bach JF; Glasser SA
    Can Vet J; 2013 Sep; 54(9):873-5. PubMed ID: 24155493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multiple neuroendocrine tumors of the pancreas].
    Sipos B
    Pathologie (Heidelb); 2024 Feb; 45(1):28-34. PubMed ID: 38180510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia.
    Dieterle MP; Husari A; Prozmann SN; Wiethoff H; Stenzinger A; Röhrich M; Pfeiffer U; Kießling WR; Engel H; Sourij H; Steinberg T; Tomakidi P; Kopf S; Szendroedi J
    Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
    Tolliver S; Graham J; Kaffenberger BH
    Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is necrolytic migratory erythema due to glucagonoma a misnomer? A more apt name might be mucosal and intertriginous erosive dermatitis.
    Grewal P; Salopek TG
    J Cutan Med Surg; 2012; 16(2):76-82. PubMed ID: 22513058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome.
    Moreno-Suárez F; Pulpillo-Ruiz Á; Fontillón Alberdi M
    Med Clin (Barc); 2017 Apr; 148(8):e45. PubMed ID: 27567335
    [No Abstract]   [Full Text] [Related]  

  • 10. Image Gallery: Necrolytic migratory erythema associated with glucagonoma.
    Aragón-Miguel R; Prieto-Barrios M; Calleja-Algarra A; Pinilla-Martin B; Rodriguez-Peralto J; Ortiz-Romero P; Rivera-Diaz R
    Br J Dermatol; 2019 Jan; 180(1):e1. PubMed ID: 30604550
    [No Abstract]   [Full Text] [Related]  

  • 11. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
    Tseng HC; Liu CT; Ho JC; Lin SH
    Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagonoma syndrome with severe erythematous rash: A rare case report.
    Wang ZX; Wang F; Zhao JG
    Medicine (Baltimore); 2019 Sep; 98(37):e17158. PubMed ID: 31517863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.
    Halvorson SA; Gilbert E; Hopkins RS; Liu H; Lopez C; Chu M; Martin M; Sheppard B
    J Gen Intern Med; 2013 Nov; 28(11):1525-9. PubMed ID: 23681843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome.
    Otto AI; Marschalko M; Zalatnai A; Toth M; Kovacs J; Harsing J; Tulassay Z; Karpati S
    J Am Acad Dermatol; 2011 Aug; 65(2):458-459. PubMed ID: 21763589
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.